Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $59000.0.

  • Avalo Therapeutics' Depreciation & Amortization (CF) rose 7352.94% to $59000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $396000.0, marking a year-over-year increase of 17500.0%. This contributed to the annual value of $169000.0 for FY2024, which is 696.2% up from last year.
  • Latest data reveals that Avalo Therapeutics reported Depreciation & Amortization (CF) of $59000.0 as of Q3 2025, which was up 7352.94% from $134000.0 recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Depreciation & Amortization (CF) registered a high of $456000.0 during Q2 2021, and its lowest value of $30000.0 during Q2 2022.
  • For the 5-year period, Avalo Therapeutics' Depreciation & Amortization (CF) averaged around $130421.1, with its median value being $43000.0 (2023).
  • Per our database at Business Quant, Avalo Therapeutics' Depreciation & Amortization (CF) tumbled by 9342.11% in 2022 and then surged by 30606.06% in 2025.
  • Over the past 5 years, Avalo Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $295000.0 in 2021, then plummeted by 88.14% to $35000.0 in 2022, then rose by 22.86% to $43000.0 in 2023, then surged by 58.14% to $68000.0 in 2024, then fell by 13.24% to $59000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $59000.0 in Q3 2025, compared to $134000.0 in Q2 2025 and $135000.0 in Q1 2025.